Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Sean Sachdev
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06499870CT.gov Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial | — | Recruiting | — | — | — |
NCT04687969CT.gov Multimodal Machine Learning Characterization of Solid Tumors | — | Completed | — | — | — |
NCT04030338CT.gov Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Piflufolastat (this asset) | Sean Sachdev | Approved | BB · 67 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Prednisone | Mayo Clinic | P3 | BB |
| Leuporelin | Mayo Clinic | P3 | BB |
| Goserelin | CancerCare Manitoba | P3 | BB |
| Bicalutamide | OHSU Knight Cancer Institute | P3 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Piflufolastat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Prostate Carcinoma | — | P4 | BB · 67 |
| Castration-Resistant Prostate Carcinoma | — | P4 | BB · 64 |
| Prostate Cancer | — | P4 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Piflufolastat in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/piflufolastat-prostate-adenocarcinoma-125832
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →